Wouter Ouwerkerk

Wouter Ouwerkerk

Auto-generated profile, based on publicly available information

Wouter Ouwerkerk

Department of Dermatology Amsterdam UMC, University of Amsterdam, Amsterdam Infection and Immunity Institute Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2017 in European Heart Journal
Verified
Journal Article
Open access
PDF file
WOW. Ouwerkerk
W. Ouwerkerk
AVA.A. Voors
A.A. Voors
SAS.D. Anker
S.D. Anker
JCJ.G. Cleland
J.G. Cleland
KDK. Dickstein
K. Dickstein
AZA.H. Zwinderman
A.H. Zwinderman
Despite clear guidelines recommendations, most patients with heart failure and reduced ejection–fraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate characteristics and for treatment-indication-bias corrected clinical outcome of patients with HFrEF that did not reach recommended treatment doses of ACE-inhibitors/Angiotensin receptor blockers (ARBs) and/or beta-blockers. BIOSTAT-CHF was specifically designed to study uptitration of ACE-inhibitors/ARBs and/or beta-blockers in 2516 heart failure patients from 69 centres in 11 European countries who were selected if they were suboptimally treated while initiation or uptitration was anticipated and encouraged. Patients who died during the uptitration period (n = 151) and patients with a LVEF > 40% (n = 242) were excluded. Median follow up was 21 months. We studied 2100 HFrEF patients (76% male; mean age 68 ±12), of which 22% achieved the recommended treatment dose for ACE-inhibitor/ARB and 12% of beta-blocker. There were marked differences between European countries. Reaching <50% of the recommended ACE-inhibitor/ARB and beta-blocker dose was associated with an increased risk of death and/or heart failure hospitalization. Patients reaching 50–99% of the recommended ACE-inhibitor/ARB and/or beta-blocker dose had comparable risk of death and/or heart failure hospitalization to those reaching ≥100%. Patients not reaching recommended dose because of symptoms, side effects and non-cardiac organ dysfunction had the highest mortality rate (for ACE-inhibitor/ARB: HR 1.72; 95% CI 1.43–2.01; for beta-blocker: HR 1.70; 95% CI 1.36–2.05). Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers seemed to have a greater risk of death and/or heart failure hospitalization compared with patients reaching ≥100%.

1 September 2018 in JACC
Verified
Journal Article
Closed access
JTJasper Tromp
Jasper Tromp
BWB. Daan Westenbrink
B. Daan Westenbrink
WOWouter Ouwerkerk
Wouter Ouwerkerk
DVDirk J. van Veldhuisen
Dirk J. van Veldhuisen
NSNilesh J. Samani
Nilesh J. Samani
AVAdriaan A. Voors
Adriaan A. Voors

14 May 2019 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
GMGeorge Markousis-Mavrogenis
George Markousis-Mavrogenis
JTJasper Tromp
Jasper Tromp
WOWouter Ouwerkerk
Wouter Ouwerkerk
MDMatt Devalaraja
Matt Devalaraja
SAStefan D. Anker
Stefan D. Anker
PMPeter Van Der Meer
Peter Van Der Meer
Aims Inflammation is a central process in the pathophysiology of heart failure (HF), but trials targeting tumour necrosis factor (TNF)‐α were largely unsuccessful. Interleukin (IL)‐6 is an important inflammatory mediator and might constitute a potential pharmacologic target in HF. However, little is known regarding the association between IL‐6 and clinical characteristics, outcomes and other inflammatory biomarkers in HF. We thus aimed to identify and characterize these associations. Methods and results Interleukin‐6 was measured in 2329 patients [89.4% with a left ventricular ejection fraction (LVEF) ≤ 40%] of the BIOSTAT‐CHF cohort. The primary outcome was all‐cause mortality and HF hospitalization during 2 years, with all‐cause, cardiovascular (CV), and non‐CV death as secondary outcomes. Approximately half (56%) of all included patients had plasma IL‐6 values greater than the previously determined 95th percentile of normal values at baseline. Elevated N‐terminal pro‐brain natriuretic peptide, procalcitonin and hepcidin, younger age, TNF‐α/IL‐1‐related biomarkers, or having iron deficiency, atrial fibrillation and LVEF > 40% independently predicted elevated IL‐6 levels. IL‐6 independently predicted the primary outcome [HR (95% confidence interval) per doubling: 1.16 (1.11–1.21), P < 0.001], all‐cause mortality [1.22 (1.16–1.29), P < 0.001] and CV as well as non‐CV mortality [1.16 (1.09–1.24), P < 0.001; 1.31 (1.18–1.45), P < 0.001], but did not improve discrimination in previously published risk models. Conclusions In a large, heterogeneous cohort of HF patients, elevated IL‐6 levels were found in more than 50% of patients and were associated with iron deficiency, reduced LVEF, atrial fibrillation and poorer clinical outcomes. These findings warrant further investigation of IL‐6 as a potential therapeutic target in specific HF subpopulations.

1 October 2014 in JACC: Heart Failure
Verified
Journal Article
Closed access
WOWouter Ouwerkerk
Wouter Ouwerkerk
AVAdriaan A. Voors
Adriaan A. Voors
AZAeilko H. Zwinderman
Aeilko H. Zwinderman

1 October 2019 in The Lancet
Verified
Journal Article
Open access
BSBernadet T Santema
Bernadet T Santema
WOWouter Ouwerkerk
Wouter Ouwerkerk
JTJasper Tromp
Jasper Tromp
ISIziah E Sama
Iziah E Sama
ARAlice Ravera
Alice Ravera
AVAdriaan A Voors
Adriaan A Voors
Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF. We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heart failure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality or hospitalisation for heart failure. Findings were validated in ASIAN-HF, an independent cohort of 3539 men and 961 women with HFrEF. Among 1308 men and 402 women with HFrEF from BIOSTAT-CHF, women were older (74 [12] years vs 70 [12] years, p<0·0001) and had lower bodyweights (72 [16] kg vs 85 [18] kg, p<0·0001) and heights (162 [7] cm vs 174 [8] cm, p<0·0001) than did men, although body-mass index did not differ significantly. A similar number of men and women reached guideline-recommended target doses of ACE inhibitors or ARBs (99 [25%] vs 304 [23%], p=0·61) and β blockers (57 [14%] vs 168 [13%], p=0·54). In men, the lowest hazards of death or hospitalisation for heart failure occurred at 100% of the recommended dose of ACE inhibitors or ARBs and β blockers, but women showed approximately 30% lower risk at only 50% of the recommended doses, with no further decrease in risk at higher dose levels. These sex differences were still present after adjusting for clinical covariates, including age and body surface area. In the ASIAN-HF registry, similar patterns were observed for both ACE inhibitors or ARBs and β blockers, with women having approximately 30% lower risk at 50% of the recommended doses, with no further benefit at higher dose levels. This study suggests that women with HFrEF might need lower doses of ACE inhibitors or ARBs and β blockers than men, and brings into question what the true optimal medical therapy is for women versus men. European Commission.

1 March 2017 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
AVAdriaan A. Voors
Adriaan A. Voors
WOWouter Ouwerkerk
Wouter Ouwerkerk
FZFaiez Zannad
Faiez Zannad
DVDirk J. van Veldhuisen
Dirk J. van Veldhuisen
NSNilesh J. Samani
Nilesh J. Samani
AZAeilko H. Zwinderman
Aeilko H. Zwinderman
Introduction From a prospective multicentre multicountry clinical trial, we developed and validated risk models to predict prospective all‐cause mortality and hospitalizations because of heart failure (HF) in patients with HF. Methods and results BIOSTAT‐CHF is a research programme designed to develop and externally validate risk models to predict all‐cause mortality and HF hospitalizations. The index cohort consisted of 2516 patients with HF from 69 centres in 11 European countries. The external validation cohort consisted of 1738 comparable patients from six centres in Scotland, UK. Patients from the index cohort had a mean age of 69 years, 27% were female, 83% were in New York Heart Association (NYHA) class II–III and the mean left ventricular ejection fraction (LVEF) was 31%. The full prediction models for mortality, hospitalization owing to HF, and the combined outcome, yielded c‐statistic values of 0.73, 0.69, and 0.71, respectively. Predictors of mortality and hospitalization owing to HF were remarkably different. The five strongest predictors of mortality were more advanced age, higher blood urea nitrogen and N‐terminal pro‐B‐type natriuretic peptide, lower haemoglobin, and failure to prescribe a beta‐blocker. The five strongest predictors of hospitalization owing to HF were more advanced age, previous hospitalization owing to HF, presence of oedema, lower systolic blood pressure and lower estimated glomerular filtration rate. Patients from the validation cohort were aged 74 years, 34% were female, 85% were in NYHA class II–III, and mean LVEF was 41%; c‐statistic values for the full and compact model were comparable to the index cohort. Conclusion A small number of variables, which are usually readily available in the routine clinical setting, provide useful prognostic information for patients with HF. Predictors of mortality were remarkably different from predictors of hospitalization owing to HF.